Your browser doesn't support javascript.
loading
Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient.
Schönborn, Linda; Thiele, Thomas; Kaderali, Lars; Günther, Albrecht; Hoffmann, Till; Seck, Sabrina Edigna; Selleng, Kathleen; Greinacher, Andreas.
Afiliación
  • Schönborn L; Institute of Immunology and Transfusion Medicine and.
  • Thiele T; Institute of Immunology and Transfusion Medicine and.
  • Kaderali L; Institute of Bioinformatics, University Medicine Greifswald, Greifswald, Germany.
  • Günther A; Hans Berger Department of Neurology, Jena University Hospital-Friedrich Schiller University, Jena, Germany; and.
  • Hoffmann T; Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Medical Faculty, Duesseldorf, Germany.
  • Seck SE; Institute of Immunology and Transfusion Medicine and.
  • Selleng K; Institute of Immunology and Transfusion Medicine and.
  • Greinacher A; Institute of Immunology and Transfusion Medicine and.
Blood ; 139(12): 1903-1907, 2022 03 24.
Article en En | MEDLINE | ID: mdl-35113987
Vaccine-induced thrombotic thrombocytopenia (VITT) is triggered by vaccination against COVID-19 with adenovirus vector vaccines (ChAdOx1 nCoV-19; Ad26.COV2-S). In this observational study, we followed VITT patients for changes in their reactivity of platelet-activating antiplatelet factor 4 (PF4) immunoglobulin G (IgG) antibodies by an anti-PF4/heparin IgG enzyme immunoassay (EIA) and a functional test for PF4-dependent, platelet-activating antibodies, and new thrombotic complications. Sixty-five VITT patients (41 females; median, 51 years; range, 18-80 years) were followed for a median of 25 weeks (range, 3-36 weeks). In 48/65 patients (73.8%; CI, 62.0% to 83.0%) the functional assay became negative. The median time to negative functional test result was 15.5 weeks (range, 5-28 weeks). In parallel, EIA optical density (OD) values decreased from median 3.12 to 1.52 (P < .0001), but seroreversion to a negative result was seen in only 14 (21.5%) patients. Five (7.5%) patients showed persistent platelet-activating antibodies and high EIA ODs for >11 weeks. None of the 29 VITT patients who received a second vaccination dose with an mRNA COVID-19 vaccine developed new thromboses or relevant increase in anti-PF4/heparin IgG EIA OD, regardless of whether PF4-dependent platelet-activating antibodies were still present. PF4-dependent platelet-activating antibodies are transient in most patients with VITT. VITT patients can safely receive a second COVID-19 mRNA-vaccine shot.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombocitopenia / Trombosis / Vacunas / COVID-19 Tipo de estudio: Observational_studies Límite: Female / Humans Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombocitopenia / Trombosis / Vacunas / COVID-19 Tipo de estudio: Observational_studies Límite: Female / Humans Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos